Current Value
$10.491 Year Return
Current Value
$10.491 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLGV | -0.02% | $977.59M | 0.09% |
ZROZ | -0.03% | $1.45B | 0.15% |
VMBS | 0.04% | $14.31B | 0.03% |
IAU | -0.04% | $45.71B | 0.25% |
TUR | -0.05% | $140.26M | 0.59% |
BAR | -0.08% | $1.11B | 0.1749% |
GLD | -0.10% | $97.40B | 0.4% |
AAAU | 0.15% | $1.47B | 0.18% |
FMF | -0.16% | $150.51M | 0.95% |
SCHQ | 0.16% | $832.77M | 0.03% |
SHY | 0.17% | $24.06B | 0.15% |
OUNZ | 0.21% | $1.63B | 0.25% |
USCI | -0.24% | $225.83M | 1.07% |
SGOL | -0.29% | $5.07B | 0.17% |
GOVI | 0.30% | $872.34M | 0.15% |
GOVZ | 0.31% | $251.12M | 0.1% |
SGOV | 0.32% | $46.49B | 0.09% |
FTGC | -0.32% | $2.41B | 1.02% |
GOVT | -0.36% | $27.32B | 0.05% |
GLDM | -0.39% | $14.45B | 0.1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -24.87% | $102.66M | 0.85% |
TAIL | -24.56% | $145.16M | 0.59% |
BTAL | -15.46% | $367.96M | 1.43% |
TFLO | -9.41% | $7.09B | 0.15% |
UNG | -8.84% | $371.70M | 1.06% |
FXY | -8.42% | $842.67M | 0.4% |
OWNS | -7.00% | $134.71M | 0.3% |
DBE | -6.66% | $47.45M | 0.77% |
JMST | -6.65% | $3.62B | 0.18% |
ULST | -6.62% | $637.67M | 0.2% |
CARY | -6.55% | $347.36M | 0.8% |
IVOL | -6.23% | $351.97M | 1.02% |
BNO | -6.00% | $83.96M | 1% |
SPTS | -5.53% | $5.76B | 0.03% |
USO | -5.23% | $957.61M | 0.6% |
USDU | -5.12% | $174.58M | 0.5% |
FTSD | -4.93% | $212.45M | 0.25% |
IBTG | -4.80% | $1.88B | 0.07% |
CTA | -4.76% | $1.03B | 0.76% |
TPMN | -4.46% | $31.21M | 0.65% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
APGE | 36.60% | $2.37B | -25.23% | 0.00% |
SYRE | 36.59% | $893.23M | -60.41% | 0.00% |
DYN | 35.33% | $1.33B | -60.18% | 0.00% |
CRNX | 34.47% | $2.93B | -38.03% | 0.00% |
EYPT | 34.13% | $377.43M | -57.61% | 0.00% |
XNCR | 34.04% | $579.33M | -61.77% | 0.00% |
SGML | 33.89% | $831.09M | -56.42% | 0.00% |
ALT | 33.29% | $438.98M | -35.74% | 0.00% |
TVTX | 33.22% | $1.87B | +210.15% | 0.00% |
IDYA | 32.44% | $1.50B | -59.71% | 0.00% |
CELC | 32.37% | $410.94M | -36.97% | 0.00% |
ELVN | 32.08% | $975.92M | -17.13% | 0.00% |
ATXS | 31.98% | $224.04M | -57.17% | 0.00% |
COGT | 31.83% | $555.62M | -36.79% | 0.00% |
RXRX | 31.40% | $1.75B | -56.94% | 0.00% |
XENE | 31.17% | $2.28B | -26.48% | 0.00% |
NUVL | 31.16% | $5.10B | -0.92% | 0.00% |
IMNM | 31.14% | $693.49M | -46.15% | 0.00% |
NOK | 30.88% | $26.62B | +31.52% | 2.75% |
VERA | 30.77% | $1.35B | -50.36% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 40.50% | $5.05B | 0.35% |
PBE | 35.05% | $219.87M | 0.58% |
IBB | 34.93% | $5.37B | 0.45% |
GNOM | 34.29% | $41.32M | 0.5% |
PTH | 33.26% | $99.62M | 0.6% |
PINK | 32.37% | $134.87M | 0.5% |
IWC | 31.96% | $765.89M | 0.6% |
ARKG | 31.27% | $947.95M | 0.75% |
BBH | 31.17% | $333.72M | 0.35% |
EFAA | 30.81% | $150.60M | 0.39% |
HFND | 30.61% | $27.95M | 1.07% |
IWO | 30.56% | $11.33B | 0.24% |
HEQT | 30.31% | $416.76M | 0.44% |
KOMP | 29.84% | $2.18B | 0.2% |
XPH | 29.20% | $139.13M | 0.35% |
HNDL | 29.07% | $685.05M | 0.97% |
FINX | 28.95% | $279.40M | 0.68% |
KJUL | 28.93% | $113.19M | 0.79% |
SFYX | 28.56% | $25.80M | 0.06% |
IWMY | 28.51% | $108.75M | 1.02% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
COOP | 0.03% | $8.24B | +54.95% | 0.00% |
ALHC | -0.05% | $2.95B | +111.49% | 0.00% |
AQB | -0.16% | $3.06M | -60.40% | 0.00% |
MOMO | 0.18% | $793.03M | +12.04% | 0.00% |
MCK | -0.18% | $85.36B | +23.70% | 0.40% |
NCMI | 0.18% | $482.84M | +5.89% | 0.00% |
ATUS | 0.20% | $1.31B | +37.93% | 0.00% |
CARV | 0.23% | $7.20M | -25.85% | 0.00% |
SWBI | 0.24% | $425.51M | -40.35% | 5.39% |
KLG | -0.26% | $1.49B | -17.13% | 3.71% |
SSSS | 0.29% | - | - | 0.00% |
GO | 0.31% | $1.32B | -35.53% | 0.00% |
MOH | 0.32% | $16.89B | -9.89% | 0.00% |
ASTH | -0.33% | $1.33B | -35.65% | 0.00% |
EZPW | -0.34% | $769.09M | +36.92% | 0.00% |
MNST | 0.34% | $59.49B | +12.46% | 0.00% |
FATBB | 0.37% | $50.08M | -14.21% | 14.95% |
NOC | 0.39% | $65.67B | -2.84% | 1.79% |
DLNG | 0.49% | $139.24M | -4.76% | 2.59% |
OKTA | 0.51% | $21.58B | +24.25% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DG | -24.98% | $19.29B | -37.83% | 2.69% |
BNED | -11.99% | $384.81M | -40.53% | 0.00% |
AGL | -11.54% | $1.11B | -49.62% | 0.00% |
DLTR | -10.69% | $18.09B | -27.56% | 0.00% |
WBA | -9.57% | $9.62B | -37.79% | 6.74% |
FMTO | -9.36% | $42.73M | -99.94% | 0.00% |
CORT | -9.24% | $7.51B | +154.55% | 0.00% |
VSTA | -7.93% | $325.62M | +10.33% | 0.00% |
OXBR | -7.65% | $14.96M | +27.20% | 0.00% |
LITB | -7.19% | $22.99M | -70.67% | 0.00% |
BIRK | -7.13% | $10.23B | +15.99% | 0.00% |
CNC | -7.09% | $29.59B | -23.84% | 0.00% |
KR | -6.68% | $43.84B | +21.99% | 1.88% |
OOMA | -5.49% | $371.79M | +79.63% | 0.00% |
BJ | -3.99% | $14.32B | +40.33% | 0.00% |
CBOE | -3.94% | $22.36B | +20.11% | 1.14% |
LFVN | -3.82% | $158.11M | +75.42% | 1.28% |
HRL | -3.80% | $16.04B | -18.09% | 3.89% |
MVO | -3.78% | $67.51M | -39.23% | 21.45% |
CABO | -3.75% | $905.51M | -58.56% | 7.36% |
Finnhub
Oruka Therapeutics Inc: * ORUKA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIALRESULTSAND PROVIDES CORPORATE UPDATE * ORUKA THERAPEUTICS: STRONG CASH POSITION OF $373...
Finnhub
MENLO PARK, Calif., April 29, 2025 -- Oruka Therapeutics, Inc. , a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin...
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Yahoo
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity and epitope demonstrated in several preclinical assays First subject dosed with ORKA-002 expected in Q3 2025 MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing
Finnhub
#64919 Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications ...
Yahoo
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, preclinical data to be presented at the 2025 AAD Annual Meeting; Phase 1 initiation expected in Q3 2025, with PK data in 1H 2026 Successful go-public transaction and over $475 million raised in 2024 $